8-K: Scilex Completes $27M Warrant Repurchase from Oramed

Scilex Holding Company announced the full exercise of its option to repurchase 6.5 million Penny Warrants from Oramed Pharmaceuticals for an aggregate of $27 million.

Summary

• Scilex Holding Company completed the exercise in full of its option to repurchase Penny Warrants from Oramed Pharmaceuticals Inc. on December 30, 2025.
• The Penny Warrants allowed Oramed to purchase up to 6,500,000 shares of common stock at an exercise price of $0.01 per share, originally issued on September 21, 2023.
• The total aggregate purchase price for the Warrant Repurchase was $27,000,000.
• Scilex had previously paid Oramed $1,500,000 in consideration for the Option Agreement, which was entered into on July 22, 2025.
• The repurchase was completed in two tranches: the first tranche for $13,000,000 in September 2025, and the second tranche for the remaining $14,000,000 on December 30, 2025.

Sentiment

Score: 6

Explanation: The completion of the warrant repurchase is a pre-announced corporate finance event that removes potential future dilution, which is generally positive for existing shareholders. However, it also represents a significant cash outflow, which could be viewed as a neutral to slightly negative impact on liquidity.

Positives

• The repurchase of 6,500,000 Penny Warrants reduces potential future dilution for existing shareholders.
• Removes an overhang of potential new shares entering the market at a very low exercise price ($0.01 per share).

Negatives

• The transaction involved a significant cash outlay of $27,000,000 for the repurchase, plus an additional $1,500,000 paid for the option, totaling $28,500,000.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance regarding future financial performance or strategic direction beyond the completion of this specific transaction.

Management Comments

• Henry Ji, Chief Executive Officer & President, signed the report on behalf of Scilex Holding Company, confirming the completion of the warrant repurchase.

Industry Context

The repurchase of warrants is a common corporate finance strategy employed by companies to manage their equity structure, reduce potential shareholder dilution, and signal confidence in the company's valuation. This action aligns with typical practices for publicly traded companies seeking to optimize their capital structure.

Stakeholder Impact

• Shareholders: Potential future dilution from the Penny Warrants is eliminated, which can be viewed positively.
• Company Liquidity: A significant cash outflow of $28,500,000 (including option consideration) impacts the company's cash reserves.

Key Dates

Recommendation

The completion of the warrant repurchase is a pre-announced corporate finance event that reduces potential future dilution but also represents a significant cash outflow. It does not fundamentally alter the company's operational outlook or financial performance in a way that would warrant a strong buy or sell recommendation based solely on this filing. Investors should consider the impact on cash reserves versus the benefit of reduced dilution within the broader context of the company's financial health and strategic initiatives.

Keywords

Scilex, SCLX, Oramed, Warrants, Repurchase, Equity, Dilution, Corporate Finance, Nasdaq